[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-405854-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-405854-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","brafv600e-metastatic-colorectal-cancer-perspective-from-a-patient-a-caregiver-and-an-oncologist","BRAFV600E Metastatic Colorectal Cancer - Perspective from a Patient, a Caregiver, and an Oncologist","","This article is co-authored by a patient with right-sided BRAFV600E metastatic colorectal cancer (mCRC), his caregiver, and an oncologist. The patient and caregiver share lived experiences of fears, expectations, and attitudes as the disease advances, including treatment challenges. The oncologist explains how BRAFV600E mCRC is managed, emphasizing balancing therapeutic goals to mitigate side effects. Improved diagnostics and multiple options—chemotherapy regimens and molecular-targeted drugs—support faster, more effective treatment algorithms. Patients’ associations are highlighted for broad support and connection to healthcare professionals.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/brafv600e-metastatic-colorectal-cancer-perspective-from-a-patient-a-caregiver-and-an-oncologist/405854/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/brafv600e-metastatic-colorectal-cancer-perspective-from-a-patient-a-caregiver-and-an-oncologist/405854.png","ImageObject",300,407,{"name":42,"@type":43},"Sophia Brooks","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What perspectives are presented in the article?","Question",{"text":63,"@type":64},"The article includes perspectives from a patient with right-sided BRAFV600E metastatic colorectal cancer, his caregiver, and an oncologist.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does the oncologist describe the goals of management for BRAFV600E mCRC?",{"text":68,"@type":64},"The oncologist discusses treatment balancing to mitigate side effects while implementing effective management strategies supported by improved diagnostics and multiple therapy options.",{"name":70,"@type":61,"acceptedAnswer":71},"What role do patients’ associations play according to the article?",{"text":72,"@type":64},"Patients’ associations provide general support for patients and close caregivers and help facilitate links with healthcare professionals, including identifying information for treatment possibilities such as clinical trials.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},405854,1791291416,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,109,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":107,"slug":108},7,40,"healthcare",{"id":110,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},8,"Research & Report",30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":106,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":4},962084925636,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Adv Ther (2023) 40:3281–3290  \n[https://doi.org/10.1007/s12325-023-02552-8](https://doi.org/10.1007/s12325-023-02552-8)  \nCOMMENTARY  \nBRAFV600E Metastatic Colorectal Cancer: Perspective from a Patient, a Caregiver, and an Oncologist  \nGuillaume Gourdin . Laure Chotel . Christelle de la Fouchardi`ere   \nReceived: March 29, 2023 / Accepted: May 12, 2023 / Published online: June 14, 2023  \n􀀂 The Author(s) 2023  \nABSTRACT  \nThis article has been co-authored by a patient with right-sided BRAFV600E metastatic colorectal cancer (mCRC), his caregiver, and an oncologist. Here the patient and caregiver discuss their personal experiences struggling with cancer, including their fears, expectations, and attitudes as the disease progresses. The oncologist describes how patients with BRAFV600E mCRCare treated and how the management strategy can be balanced to mitigate any side effects. Improved diagnostic techniques and the availability of numerous treatment options, including various chemotherapy schemes and molecular-targeted drugs, can aid rapid implementation of treatment algorithms. The pivotal roles of patients’ associations in the general support of patients and those close to them, and in facilitating the link with healthcare  \nG. Gourdin  \nPatient Author, Nancy, France  \nL. Chotel  \nCaregiver Author, Nancy, France  \n[C. de](C. de) la Fouchardi`ere  \nCentre L´eon B´erard, 28, rue Laennec, 69373 Lyon cedex 08, France  \n[C. de](C. de) la Fouchardi`ere (&)  \nInstitut Paoli-Calmettes, 232 Boulevard SainteMarguerite, 13009 Marseille, France  \ne-mail: [delafouchardierec@ipc.unicancer.fr](delafouchardierec@ipc.unicancer.fr)  \nprofessionals, are highlighted in this perspective piece.  \nPLAIN LANGUAGE SUMMARY  \nThis article has been co-authored by a French patient with BRAFV600E metastatic colorectal cancer since December 2020, his caregiver, and an oncologist, a French physician currently based at the Institut Paoli-Calmettes in Marseille. Metastatic colorectal cancer is characterized by a high number of genetic mutations, each being associated with a different prognosis and response to treatment. Around 8–12% of patients with metastatic colorectal cancer will present with a BRAF mutation in their tumour, the majority of which are V600E, leading to a poor response to standard chemotherapy and short overall survival. The patient and caregiver discuss their personal experiences of struggling with BRAFV600E metastatic colorectal cancer, including their fears and expectations, as the disease progresses. The patient is currently receiving immunotherapy as his fifth line of treatment, while his caregiver actively communicates with patients’ associations to understand more about the disease and identify new treatment possibilities. The treatment lines received by the patient did not follow the usual treatment algorithms proposed in France for  \npatients with BRAFV600E-mutated metastatic colorectal cancer. The caregiver sought a clinical trial for the patient’s third-line treatment from information provided by patients’ associations. Thus, patients’ associations play a key role in the general support of patients and those close to them, and in facilitating the link with healthcare professionals.  \nKeywords: BRAFV600E metastatic colorectal cancer; Metastatic; Oncology; Patient perspective; Caregiver  \nKey Summary Points  \nThis article has been co-authored by a patient with right-sided BRAFV600E metastatic colorectal cancer (mCRC), his caregiver, and an oncologist.  \nThe patient and caregiver describe their personal experiences, the history of the illness, the various treatments received, and the difficulties encountered.  \nThe physician describes the main characteristics of BRAFV600E mCRC and discusses which treatments were used for the patient.  \nThe importance of shared decisionmaking and the pivotal role of patients’associations in the general support of patients and those close to them, and in facilitating the link with healthcare professionals, a","cbCairtgKYvkavB5","https://ap.wps.com/l/cbCairtgKYvkavB5","pdf",267162,"English","# Abstract\n## Plain language summary\n## Patient and caregiver’s perspectives","[{\"question\":\"What perspectives are presented in the article?\",\"answer\":\"The article includes perspectives from a patient with right-sided BRAFV600E metastatic colorectal cancer, his caregiver, and an oncologist.\"},{\"question\":\"How does the oncologist describe the goals of management for BRAFV600E mCRC?\",\"answer\":\"The oncologist discusses treatment balancing to mitigate side effects while implementing effective management strategies supported by improved diagnostics and multiple therapy options.\"},{\"question\":\"What role do patients’ associations play according to the article?\",\"answer\":\"Patients’ associations provide general support for patients and close caregivers and help facilitate links with healthcare professionals, including identifying information for treatment possibilities such as clinical trials.\"}]","BRAFV600E Metastatic Colorectal Cancer - Perspective from a Patient, a Caregiver, and an Oncologist | PDF",1790562134,25]